Oligonucleotide therapeutics have unlocked new treatment possibilities for rare and fatal diseases often associated with undruggable proteins.1 Here, ...
Today, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned su...
Dermatology industry veteran Thibaud Portal, PhD appointed as CEO Granular Therapeutics, (Granular) a private biotech company specialising in p...
Patients with inflammatory diseases being treated with therapeutic monoclonal antibodies (mAbs) such as Infliximab may experience a significant increase in...
The four founding members of NRG’s International SAB are US-based and bring in-depth translational expertise in neuroscience and drug discovery acros...
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer tre...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate adv...
Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- ...
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it h...
Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing ...
© 2025 Biopharma Boardroom. All Rights Reserved.
